Back to compounds

COMPOUND PROFILE / COMBINATIONS

CagriSema.

Research draft

CagriSema is the clinically developed combination of cagrilintide and semaglutide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

CagriSema is the clinically developed combination of cagrilintide and semaglutide.

CLASSIFICATIONCombinations
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCombination

Mechanism

It combines amylin-related satiety signalling with GLP-1 receptor activity.

Human research

Direct randomised combination studies exist, including phase 3 diabetes research; this is stronger evidence than combining monotherapy claims.

Preclinical & other research

Component mechanisms support a rationale, while combination trials determine clinical outcomes.

Safety & unknowns

Gastrointestinal effects and trial-specific eligibility matter. Clinical formulations do not authenticate grey-market blends.

Regulatory status

Authorisation must be checked for the exact combination and jurisdiction; cross-link Semaglutide + Cagrilintide.

Reported use & evidence

Research profile draft

The supplied CagriSema profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds